LONGEVERON INC. news, videos and press releases
For more news please use our advanced search feature.
LONGEVERON INC. - More news...
LONGEVERON INC. - More news...
- Longeveron to Present at the Planet MicroCap Showcase
- Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
- Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
- Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
- Longeveron Announces Closing of $5.2 Million Public Offering
- Longeveron Announces Pricing of $5.25 Million Public Offering
- Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
- Longeveron Announces 1-for-10 Reverse Stock Split
- Longeveron Reports Year-End 2023 Results and Provides Corporate Update
- Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
- Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
- Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
- Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association
- Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
- Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023
- Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s
- Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
- Longeveron Issues Letter to Stockholders
- Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
- Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
- Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
- Longeveron Rights Offering Subscription Period Begins
- Longeveron Rights Offering Declared Effective and Calendar Finalized
- Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
- Longeveron Announces Pricing for Rights Offering and Expected Calendar